ABMT:OTC-Advanced Biomedical Technologies, Inc (USD)

COMMON STOCK | Medical Devices | OTC

Last Closing Price

USD 0.26

Change

0.00 (0.00)%

Market Cap

USD 0.02B

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Advanced Biomedical Technologies, Inc., a development stage company, designs, develops, manufactures, and markets biomaterial internal fixation devices. It offers polymer osteosynthesis devices, which include surgical screws, binding wires, rods, and related medical devices for the treatment of orthopedic trauma, sports-related medical treatment, cartilage repair, and related treatments, as well as for reconstructive dental procedures. The company was formerly known as Geostar Mineral Corporation and changed its name to Advanced Biomedical Technologies, Inc. in March 2009. Advanced Biomedical Technologies, Inc. was founded in 2002 and is based in New York, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-27 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SNNUF Smith & Nephew plc

N/A

USD15.51B 41.48 20.83
CHEOF Cochlear Limited

N/A

USD10.83B 45.76 23.12
CHEOY Cochlear Limited

+2.25 (+2.74%)

USD10.83B 43.23 23.12
GNNDY GN Store Nord A/S

N/A

USD9.93B 50.50 3.87
GGNDF GN Store Nord A/S

N/A

USD9.93B 53.60 3.87
MCRPF MicroPort Scientific Corporati..

N/A

USD7.32B 219.70 53.08
NHNKY Nihon Kohden Corporation

-0.74 (-4.50%)

USD2.73B 24.28 0.12
DWRKF Drägerwerk AG & Co. KGaA

N/A

USD1.93B 52.39 N/A
CYBQY CYBERDYNE Inc

-0.05 (-0.58%)

USD1.85B 1,576.18 1.53
MEDGF Medacta Group SA

N/A

USD1.84B 155.58 41.48

ETFs Containing ABMT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 160.00% 76% C 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 160.00% 76% C 88% B+
Trailing 12 Months  
Capital Gain 73.33% 65% D 79% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 73.33% 65% D 79% C+
Trailing 5 Years  
Capital Gain 85.71% 72% C- 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 85.71% 72% C- 73% C
Average Annual (5 Year Horizon)  
Capital Gain 21.20% N/A N/A 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.20% N/A N/A 69% D+
Risk Return Profile  
Volatility (Standard Deviation) 88.77% N/A N/A 28% F
Risk Adjusted Return 23.88% N/A N/A 58% F
Market Capitalization 0.02B 59% F 44% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -24.31 83% B 90% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 42.36% 69% D+ 88% B+
Return on Assets -124.30% 30% F 10% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta -1.22 96% A 91% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.